Difficult Intraoperative Heparinization Following Andexanet Alfa Administration

Area of Science:

• Cardiology
• Pharmacology
• Vascular Surgery

Background:

• Direct oral anticoagulants (DOACs) are widely prescribed for thrombotic conditions.
• Reversal agents for DOACs, such as andexanet alfa (AnXa), are emerging therapies.
• Factor Xa inhibitors, like rivaroxaban, are a significant class of DOACs.

Observation:

• A 70-year-old male on rivaroxaban presented with a ruptured abdominal aortic aneurysm and hemodynamic instability.
• Andexanet alfa was administered to reverse the anticoagulant effect of rivaroxaban prior to endovascular repair.
• Intraoperative heparinization for graft placement was not feasible following AnXa administration.

Findings:

• Andexanet alfa effectively reversed rivaroxaban's anticoagulant activity in a patient with a ruptured abdominal aortic aneurysm.
• The administration of andexanet alfa posed a challenge for subsequent re-anticoagulation during complex vascular surgery.
• This case underscores the potential difficulties in managing anticoagulation in emergent surgical settings after reversal agent use.

Implications:

• Careful consideration of the risks and benefits of andexanet alfa is crucial in patients requiring subsequent anticoagulation.
• Further research is needed to establish protocols for re-anticoagulation following the use of reversal agents in emergent surgical scenarios.
• This case highlights the evolving landscape of anticoagulant reversal and its impact on perioperative management.